Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bioventus (BVS) Deferred Taxes (2020 - 2025)

Bioventus' Deferred Taxes history spans 6 years, with the latest figure at -$1.1 million for Q4 2025.

  • For Q4 2025, Deferred Taxes fell 135.18% year-over-year to -$1.1 million; the TTM value through Dec 2025 reached -$909000.0, up 83.15%, while the annual FY2025 figure was -$909000.0, 83.15% up from the prior year.
  • Deferred Taxes reached -$1.1 million in Q4 2025 per BVS's latest filing, down from $135000.0 in the prior quarter.
  • In the past five years, Deferred Taxes ranged from a high of $3.2 million in Q4 2024 to a low of -$17.0 million in Q2 2022.
  • Average Deferred Taxes over 5 years is -$3.4 million, with a median of -$876000.0 recorded in 2023.
  • Peak YoY movement for Deferred Taxes: tumbled 20603.61% in 2022, then surged 176.44% in 2024.
  • A 5-year view of Deferred Taxes shows it stood at -$8.1 million in 2021, then tumbled by 46.14% to -$11.8 million in 2022, then soared by 109.88% to $1.2 million in 2023, then surged by 176.44% to $3.2 million in 2024, then tumbled by 135.18% to -$1.1 million in 2025.
  • Per Business Quant, the three most recent readings for BVS's Deferred Taxes are -$1.1 million (Q4 2025), $135000.0 (Q3 2025), and $44000.0 (Q2 2025).